publication venue for
- Unresolved issues in the use of direct acting oral anticoagulants. 21:913-921. 2023
- Cardiac troponin testing in cardiac surgery. 21:729-731. 2023
- Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease?. 21:305-309. 2023
- Implantable loop recorders in patients with atrial fibrillation. 20:919-928. 2022
- Management and outcomes of acute myocardial infarction in patients with preexisting heart failure: an analysis of 2 million patients from the national inpatient sample. 20:233-240. 2022
- Screening for undiagnosed atrial fibrillation. 16:591-598. 2018
- Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with bioprosthetic valves. 16:413-418. 2018
- Catheter-directed thrombolysis for extensive iliofemoral deep vein thrombosis: review of literature and ongoing trials. 14:189-200. 2016
- Predicting cardiovascular disease from handgrip strength: the potential clinical implications. 13:1277-1279. 2015
- Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants. 13:1213-1223. 2015
- Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives. 12:963-976. 2014
- Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial. 10:965-972. 2012
- The older patient with heart failure: high risk for frailty and cognitive impairment. 10:779-795. 2012
- For a rapid diagnosis of acute myocardial infarction, a sensitive troponin assay is needed in the near-patient testing setting. 10:309-312. 2012
- Gastroesophageal reflux and atrial fibrillation: is there any correlation?. 10:317-322. 2012
- Are endothelial progenitor cells a prognostic factor in patients with heart failure?. 10:167-175. 2012
- Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. 9:279-286. 2011
- Blocking the renin–angiotensin system: dual- versus mono-therapy. 7:667-674. 2009
- Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6. 7:241-249. 2009
- The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. 7:9-16. 2009
- Arterial thrombosis in children. 6:419-428. 2008
- Venous thrombosis in children. 6:411-418. 2008